The company’s primary sales markets drove the quarterly performance, contributing SEK 914.9 million to the total. While regional results varied, North America emerged as a significant growth engine, recording a 51 percent surge in quarterly revenue to SEK 207.8 million. South American operations also saw triple-digit expansion, albeit from a smaller base, jumping 326 percent to SEK 10.2 million.

Performance across other territories proved mixed. Central Europe maintained steady momentum with a 28 percent increase, totaling SEK 280.7 million. Conversely, markets in Eastern Europe and the Asia-Pacific region faced headwinds, with revenues contracting by 9 percent each during the same period. Faun Pharma, the group’s manufacturing subsidiary, added SEK 15.3 million to the total quarterly revenue, reflecting a modest 2 percent year-over-year improvement.